Novel application of scutellarein

A technology of scutellarein and neovascularization, which is applied in the field of application of scutellarein in the preparation of drugs for the treatment of neovascularization, to achieve the effects of high curative effect, small dose, and resistance to drugs

Inactive Publication Date: 2014-03-26
CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent document ZL201110004216.1 discloses the application of formononetin in inhibiting angiogenesis. Vascular dependence and neovascularization-related diseases, but there is no report about the application of scutellarein in inhibiting neovascularization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of scutellarein
  • Novel application of scutellarein
  • Novel application of scutellarein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Inhibitory effect of scutellarein on the proliferation of human umbilical vein endothelial cells

[0026] Experimental materials: umbilical endothelial cells (HUVEC) were provided by the Drug Research Institute of Qilu Pharmaceutical Company, the seventh generation; chicken embryos were provided by Shandong SPF breeder farm, SD (Sprague Dawley) rats were provided by the Animal Center of Shandong University of Traditional Chinese Medicine, VEGF Transgenic zebrafish were provided by Shandong Academy of Sciences.

[0027] 1.1 Experimental content: observe the inhibitory effect of scutellarein at multiple concentrations on the proliferation inhibition of endothelial cells.

[0028] HUVEC were diluted to 1×10 with serum-free M199 medium 5 cells / ml, inoculate 100 μl per well in 96-well culture plate, add 2% fibroblast growth factor (bGFG) to each well, and place the 96-well plate in a CO2 incubator for 24 h. After the cells adhered to the wall, the medium was r...

Embodiment 2

[0034] Example 2: Inhibitory Experiment of Scutellarein on Migration of Human Umbilical Vein Endothelial Cells

[0035] Experimental materials: umbilical endothelial cells (HUVEC) were provided by Qilu Pharmaceutical Company Drug Research Institute, the seventh generation.

[0036] 1.1 Experimental content: observe the effect of different concentrations of compounds on the migration ability of vascular endothelial cells.

[0037] 1.2 Experimental method: Refer to Burk's method to improve it. Culture umbilical endothelial cells in a 24-well plate. When the cell abundance is above 95%, use a 200 μl pipette tip to draw a straight line in the well, and wash it twice with Hank's solution. Add the drug-containing M199 medium to continue culturing for 24 hours, take out the culture, record the results with an inverted microscope, count the distance between the cells between the streaks, and calculate the migration inhibition rate according to the following formula:

[0038]

[...

Embodiment 3

[0042] Example 3: Effect of scutellarein on microvessel formation in rat arterial ring

[0043] 3.1 The testing principle of the drug screening model

[0044] The rat arterial ring microangiogenesis model was used to observe the effect of drugs on the angiogenesis of rat arterial rings, and indirectly measure the ability of drugs to affect angiogenesis.

[0045] 3.2 Experimental results

[0046] From the experimental results, the microvessels grown from the vascular tissue in the control group were radial and flake-like, and each group of scutellarein showed a sparse and scattered inhibition of microvessel growth, and showed a dose-dependent effect, 40μg·ml -1 Scutellarein showed a significant decrease in microvessel density, 120μg·ml -1 Individual cell growth can be seen basically, and no microvascular structure appears. The results of the rat arterial ring inhibition experiment are shown in image 3 , in the figure, A: control group; B: scutellarein 80 μg·ml -1 ; C: s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the application of scutellarein in the preparation of drugs for treating neovascularization. Background technique [0002] Angiogenesis refers to the process of sprouting new blood vessels from existing blood vessels, which is related to the migration and proliferation of vascular endothelial cells. Embryonic development is accompanied by angiogenesis, but except for wound healing, female menstruation, and some pathological processes, angiogenesis rarely occurs in adults. Studies have shown that tumors themselves have the ability to initiate and promote angiogenesis to meet their own metabolism and nutrient supply needs. Tumor neovascularization starts from the pre-existing vascular bed. If there is no angiogenesis, the growth of the primary tumor will not exceed 1-2mm, and there will be no invasion and metastasis. Inhibiting tumor angiogenesis is closely related to blocking tumor occurre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P35/00A61P35/02A61P19/02A61P29/00A61P27/02A61P17/02
Inventor 段俊国陶铮路雪婧张富文
Owner CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap